Recent Material Events

Track the latest material events (8-K filings) with AI-powered analysis. Stay informed about major corporate developments, acquisitions, and changes.

📊 868 Events

🤖 AI Analyzed

Recent

📄 Page 2 of 73

Presurance Holdings, Inc.

8-K March 30, 2026

Key Highlights

Strategic exit from commercial insurance completed, eliminating future liability...
Personal insurance segment shows strong momentum with 12.7% YoY premium growth.
Business model successfully simplified to focus exclusively on core personal lin...

Read Analysis

🤖 AI Generated

Lunai Bioworks Inc.

8-K March 30, 2026

Key Highlights

Acquisition of Clemann Group IP to enable blood-brain barrier drug delivery
Strategic pivot from service model to high-value proprietary drug developer
Raised $20 million in Series B funding to extend cash runway to 24 months

Read Analysis

🤖 AI Generated

Sight Sciences, Inc.

8-K March 30, 2026

Key Highlights

Federal court ruled Alcon willfully infringed on Sight Sciences' OMNI patents.
Awarded $34 million in damages plus a 10% royalty on future U.S. Hydrus sales.
Strategic pivot to focus exclusively on high-margin surgical glaucoma tools.

Read Analysis

🤖 AI Generated

Tempest Therapeutics, Inc.

8-K March 30, 2026

Key Highlights

Promising clinical data for TPST-2003 with a 100% response rate in early trials
Strategic pivot to a specialized cell therapy model
Appointment of Dr. Matt Angel as CEO to lead the transition

Read Analysis

🤖 AI Generated

Weave Communications, Inc.

8-K March 30, 2026

Key Highlights

Cooperation agreement with activist investors Engine Capital and 2717 Partners.
Board expansion to include two activist-nominated directors, increasing oversigh...
Formation of a new Finance Committee to enforce stricter cost controls and opera...

Read Analysis

🤖 AI Generated

zSpace, Inc.

8-K March 30, 2026

Key Highlights

Successful pivot to a high-margin, software-first business model (52% of revenue...
Improved gross profit margins from 41% to 48%
Secured $7.3 million in new funding to extend operational runway through 2026

Read Analysis

🤖 AI Generated

Kezar Life Sciences, Inc.

8-K March 30, 2026

Key Highlights

Acquisition of Kezar Life Sciences by Aurinia Pharmaceuticals
Guaranteed cash payment of $6.955 per share for KZR shareholders
Additional upside potential via non-tradable Contingent Value Rights (CVRs)

Read Analysis

🤖 AI Generated

ADDENTAX GROUP CORP.

8-K March 30, 2026

Key Highlights

Acquisition of 62.18% controlling stake in Keemo Fashion Group
Strategic vertical integration to control garment supply chain
Non-cash transaction preserving $1.2 million in liquid cash reserves

Read Analysis

🤖 AI Generated

Quince Therapeutics, Inc.

8-K March 30, 2026

Key Highlights

Debt reduction of $16.4 million settled for only $5.5 million
Significant balance sheet cleanup removes restrictive covenants
Strategic pivot toward a potential merger or acquisition

Read Analysis

🤖 AI Generated

Fat Brands, Inc

8-K March 30, 2026

Key Highlights

Court-ordered restructuring and mandatory sale of 18 restaurant chains.
Complete removal of former CEO Andrew Wiederhorn from all management and influen...
Transition to a board composed primarily of independent directors.

Read Analysis

🤖 AI Generated

Ensysce Biosciences, Inc.

8-K March 30, 2026

Key Highlights

Active search for a buyer or strategic partner
Focus on proprietary abuse-deterrent opioid technology
Management stability prioritized by the board to facilitate potential sale

Read Analysis

🤖 AI Generated

InMed Pharmaceuticals Inc.

8-K March 30, 2026

Key Highlights

Active development of clinical-stage drug candidates INM-901 and INM-755
Company remains fully operational with no disruption to clinical trials
180-day grace period provided by Nasdaq to regain compliance

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from material event filings with our AI-powered analysis. Track corporate developments, acquisitions, and strategic changes.

Back to Homepage